‘You Just Got Better at Making Money’: Democrats Blast Celgene, Teva for Price Hikes Detailed in Internal Documents
From the time Oversight Committee Chairman Carolyn Maloney (D-N.Y.) gaveled Wednesday’s hearing to order, Democrats seemed intent on making it an extended pitch for their signature drug pricing bill, known as H.R. 3, which would allow Medicare to negotiate over drug prices, akin to the way that many European governments negotiate for drugs and other health care services.... Teva’s Schultz was the clear loser of Wednesday’s hearing. He declined to answer nearly all of the questions posed to him about Teva’s behavior because, he claimed, they dealt with decisions which happened before he took over as CEO in 2017. By the second hour, lawmakers were so frustrated with his answers that began openly insulting Schultz. “I just want to congratulate you on being able to answer, from my estimate, about 50 percent of these questions by saying you weren’t there,” said Rep. John Sarbanes (D-Md.) “It would have been nice to come, maybe, equipped a little bit better.” “You might as well get off the screen,” Gomez added, referring to Schultz’s appearance via video conference.